93 related articles for article (PubMed ID: 430374)
1. SC 25152: a potent mineralocorticoid antagonist with decreased antiandrogenic activity relative to spironolactone.
Cutler GB; Sauer MA; Loriaux DL
J Pharmacol Exp Ther; 1979 Apr; 209(1):144-6. PubMed ID: 430374
[TBL] [Abstract][Full Text] [Related]
2. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo M; Joss U; Ramjoué HP; Whitebread SE; Haenni H; Schenkel L; Kraehenbuehl C; Biollaz M; Grob J; Schmidlin J
J Pharmacol Exp Ther; 1987 Feb; 240(2):650-6. PubMed ID: 2949071
[TBL] [Abstract][Full Text] [Related]
3. SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate.
Cutler GB; Pita JC; Rifka SM; Menard RH; Sauer MA; Loriaux DL
J Clin Endocrinol Metab; 1978 Jul; 47(1):171-5. PubMed ID: 263288
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies on the endocrine side effects of new aldosterone antagonists.
Nishino Y; Schröder H; el Etreby MF
Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852
[TBL] [Abstract][Full Text] [Related]
5. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
6. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Casals-Stenzel J; Buse M; Wambach G; Losert W
Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
[TBL] [Abstract][Full Text] [Related]
7. A comparison of in vitro and in vivo EDSTAC test battery results for detecting antiandrogenic activity.
Charles GD; Kan HL; Schisler MR; Bhaskar Gollapudi B; Sue Marty M
Toxicol Appl Pharmacol; 2005 Jan; 202(1):108-20. PubMed ID: 15589981
[TBL] [Abstract][Full Text] [Related]
8. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic effects of topically applied spironolactone on the hamster flank organ.
Weissmann A; Bowden J; Frank BL; Horwitz SN; Frost P
Arch Dermatol; 1985 Jan; 121(1):57-62. PubMed ID: 3155605
[TBL] [Abstract][Full Text] [Related]
10. Cimetidine is an antiandrogen in the rat.
Winters SJ; Banks JL; Loriaux DL
Gastroenterology; 1979 Mar; 76(3):504-8. PubMed ID: 428705
[TBL] [Abstract][Full Text] [Related]
11. [Direct action of mineralocorticoid antagonists on biosynthesis of aldosterone: comparative activities of several new compounds].
Netchitailo P; Perroteau I; Delarue C; Leboulenger F; Capron MH; Vaudry H
Can J Physiol Pharmacol; 1983 Jan; 61(1):23-8. PubMed ID: 6301660
[TBL] [Abstract][Full Text] [Related]
12. The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
Ménard J
Mol Cell Endocrinol; 2004 Mar; 217(1-2):45-52. PubMed ID: 15134800
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogenic effect of spironolactone in rats.
Basinger GT; Gittes RF
J Urol; 1974 Jan; 111(1):77-80. PubMed ID: 4813557
[No Abstract] [Full Text] [Related]
14. [Doses levorin display an antiandrogenic action?].
Kharitonenko TS; Lishnevskaia EB; Shneĭ IV; Sizova IA; Mikhaĭlets GA
Antibiotiki; 1979 Oct; 24(10):772-6. PubMed ID: 556230
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogenic and antirenotropic effect of spironolactone.
Broulik PD; Stárka L
Endokrinologie; 1976 Oct; 68(1):35-9. PubMed ID: 1001267
[TBL] [Abstract][Full Text] [Related]
16. Prostate effect in dogs with the aldosterone receptor blocker eplerenone.
Levin S; McMahon E; John-Baptiste A; Bell RR
Toxicol Pathol; 2013 Feb; 41(2):271-9. PubMed ID: 23242577
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic activities of Glycyrrhiza glabra in male rats.
Zamansoltani F; Nassiri-Asl M; Sarookhani MR; Jahani-Hashemi H; Zangivand AA
Int J Androl; 2009 Aug; 32(4):417-22. PubMed ID: 19515171
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor binding and antiandrogenic activity of some 4,5-secoandrostanes and ring B cyclopropanoandrostanes.
Stárka L; Hampl R; Kasal A; Kohout L
J Steroid Biochem; 1982 Sep; 17(3):331-4. PubMed ID: 6215537
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro.
Weindel K; Lewicka S; Vecsei P
Arzneimittelforschung; 1991 Sep; 41(9):946-9. PubMed ID: 1796922
[TBL] [Abstract][Full Text] [Related]
20. (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
Kinoyama I; Taniguchi N; Toyoshima A; Nozawa E; Kamikubo T; Imamura M; Matsuhisa A; Samizu K; Kawanimani E; Niimi T; Hamada N; Koutoku H; Furutani T; Kudoh M; Okada M; Ohta M; Tsukamoto S
J Med Chem; 2006 Jan; 49(2):716-26. PubMed ID: 16420057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
